Weekly Digests
‹ Back to May

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

May 24, 2017

The presence of tumor-associated macrophages (TAMs) in a tumor microenvironment (TME) is usually associated with worse outcomes for patients. However, recent research and ongoing clinical trials have demonstrated that therapies blocking the interaction between SIRPα and CD47 can induce TAMs to phagocytose tumor cells, providing therapeutic benefit.

Gordon et al. set out to explore other mechanisms that might regulate the function of macrophages in the TME. Knowing that macrophages have been shown to express PD-1 in some instances of infection, the team wondered whether the same could be true of macrophages in tumors. Using a murine colon cancer model, they found about 50% of the tumor-infiltrating macrophages expressed surface PD-1, confirming their hypothesis.

TAMs are typically distinguished as either inflammatory “M1” or pro-tumor “M2” macrophages. Using flow cytometry, the researchers found that while most PD-1- TAMs resembled M1 cells, almost all PD-1+ TAMs expressed an M2 phenotype, indicating that PD-1 expression is likely associated with pro-tumor traits. The researchers also noted that the PD-1+ TAM population only began to emerge two weeks after tumor engraftment and then accumulated over time during tumor progression. Similarly, in human colorectal cancer samples, the frequency of PD-1+ macrophages within the tumor increased with disease stage and was associated with an M2 phenotype. The time-dependent increase in PD-1+ TAMs was due to circulating bone marrow-derived macrophages homing in on the inflammatory TME rather than from the expansion of resident immune cells, as shown with bone marrow transplantation experiments.

Compared to their PD-1- counterparts, PD-1+ TAMs showed altered expression patterns and morphology. They expressed more M2-associated scavenger receptor CD206, less MHC class II, and more CD111c. Stained PD-1+ TAMs appeared large and foamy, indicating that they were filled with vacuoles and/or lipids, and electron microscopy confirmed that this foamy appearance was due, at least in part, to an accumulation of uncleared phagocytic material and lysosomes in the cytoplasm.

A series of ex vivo and in vivo experiments revealed that, much like its role in T cells, PD-1 expression on TAMs induced ‘exhaustion’ and limited the effector functions of activated TAMs by decreasing their ability to phagocytose tumor cells. Experiments in mice lacking an adaptive immune system confirmed that this decrease in phagocytosis by PD-1+ TAMs could be overturned by a knockout of PD-L1 in the tumor. Mice whose tumors did not express PD-L1 also showed reduced tumor burden after three weeks compared to mice with tumors that overexpressed PD-L1.

The researchers next treated mice with either a PD-1 or PD-L1 blockade and observed a significant reduction in tumor growth. Depletion of TAMs repealed this effect, indicating the direct role of TAMs in the antitumor efficacy. Further, the researchers tested these blockades in combination with anti-CD47 immunotherapy, which is already being tested in early clinical trials, to explore how the two therapy types would interact. Individually, the PD-L1 and CD47 blocking therapies equivalently reduced tumor size, while the combination of the two therapies showed a trend toward greater reduction of tumor burden and greater survival benefit.

Although blockade of the PD-1 axis is typically considered a T cell-directed therapy, the PD-1 expression observed on B cells, dendritic cells, natural killer cells, and now on tumor-associated macrophages, indicates that this axis is important to both the innate and adaptive arms of the immune system. The breadth of cell types expressing PD-1 may explain the effects of PD-1/PD-L1 inhibition in situations where T cell activity might be compromised.

by Lauren Hitchings


Gordon S.R., Maute R.L., Dulken B.W., Hutter G., George B.M., McCracken M.N., Gupta R., Tsai J.M., Sinha R., Corey D., Ring A.M., Connolly A.J., Weissman I.L. PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017 May 25.

In the Spotlight...

Converting lymphoma cells into potent antigen-presenting cells for interferon-induced tumor regression.

Targeting B cell lymphoma with interferon alpha (IFNɑ) fused to an anti-CD20 antibody eliminated the cancer’s resistance to anti-CD20 therapy in murine models because the inclusion of IFNɑ converted cancer cells into potent antigen-presenting cells that re-activated CD8+ tumor infiltrating lymphocytes, which then targeted and killed the cancer cells.

Chimeric PD-1:28 receptor upgrades low-avidity T cells and restores effector function of tumor-infiltrating lymphocytes for adoptive cell therapy.

T cells containing low affinity TCRs are not sufficiently activated for tumor elimination; however, when Schlenker et al. inserted a chimeric PD-1:28 receptor, effector function could be increased to levels of high avidity T cells. Th1 function could be restored in disabled TILs from human tumors, but improved tumor control in the mouse could not be demonstrated.

Expansion of tumor-infiltrating CD8+ T cells expressing PD-1 improves the efficacy of adoptive T cell therapy.

In two mouse tumor models, the PD-1+ subset of CD8+ TILs contained the majority of tumor-specific cells, which could thus be readily isolated without previous knowledge of their antigen specificities. The PD-1+ CD8+ T cells (expanded in vitro) were better than their PD-1- or bulk CD8+ counterparts at containing tumor progression in vivo, and their efficacy was enhanced by PD-L1 blockade.

Targeted calcium influx boosts cytotoxic T lymphocyte function in the tumour microenvironment.

This study describes a TGFβ-induced pathway by which Treg cells suppress the cytotoxic activity of CD8+ T cells by dysregulating the intracellular calcium signaling needed to trigger degranulation. It also provides evidence for an approach to regulate the cytotoxic function of engineered T lymphocytes via highly selective optical control of Ca2+ influx with light-sensitive channelrhodopsin.

T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth.

Inderburg et al. used T cell receptor transfer to confer reactivity against a recurrent frameshift mutation in the TGFβ receptor II to human T cells and demonstrated efficacy in a colon cancer xenograft mouse model, limiting off-target toxicity with this approach.

Everything New this Week In...

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.